Nice work @vitti10 @GaiaGriguolo I am wondering whether these differences are a true evolution of the “molecular phenotype” or if they could be largely explain by intra-tumor heterogeneity (core biopsy # surgical samples) and pre- and post-analytical factors #ESMO21 Tweet added by Giampaolo Bianchini @BianchiniGP

Giampaolo Bianchini

3 years

Nice work @vitti10 @GaiaGriguolo I am wondering whether these differences are a true evolution of the “molecular phenotype” or if they could be largely explain by intra-tumor heterogeneity (core biopsy # surgical samples) and pre- and post-analytical factors #ESMO21

Aleix Prat #PrecisionOncology

@prat_aleix

3 years

📢 #ESMO21 E-poster: "HER2-low breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment" by Dr. Miglietta @vitti10 @GaiaGriguolo HER2-low expression showed high instability from primary BC to RD after neoadjuvant treatment

0

18

45

2

3

18

Aleix Prat #PrecisionOncology

@prat_aleix

3 years

@BianchiniGP @vitti10 @GaiaGriguolo agree, probably a mix of things, but inter-pathologist reproducibility of HER2low disease is a major issue. Kappa concordance scores were horrible in our study: @FrancescoSche20

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

npj Breast Cancer - Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

www.nature.com

2

3

8

Aleix Prat #PrecisionOncology

@prat_aleix

3 years

@BianchiniGP @vitti10 @GaiaGriguolo another bigger question is if any detection of HER2 levels by IHC are need to respond to potent antiHER2 therapies Hopefully @FAndreMD @GroupeUNICANCER DAISY trial can shed some light

1

3

10

Replies